A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

NCT01225731 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

355

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: tildrakizumab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC